Nautilus Biotech S.A.
Nautilus Biotech S.A., headquartered in France, is a pioneering company in the biotechnology sector, specialising in the development of innovative protein-based therapeutics. Founded in 2015, Nautilus has rapidly established itself as a leader in the biopharmaceutical industry, focusing on advanced drug discovery and development processes that leverage cutting-edge technologies. With a strong presence in Europe and expanding operations globally, Nautilus Biotech is renowned for its unique approach to protein engineering, which enhances the efficacy and safety of therapeutic proteins. The company’s core offerings include bespoke protein design and optimisation services, setting it apart in a competitive market. Nautilus has achieved significant milestones, including strategic partnerships and successful product launches, solidifying its position as a key player in the biotechnology landscape.
DitchCarbon Score
How does Nautilus Biotech S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nautilus Biotech S.A.'s score of 26 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nautilus Biotech S.A.'s reported carbon emissions
Nautilus Biotech S.A., headquartered in France, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Consequently, there are no documented Scope 1, 2, or 3 emissions to analyse. Additionally, the company has not established any formal reduction targets or commitments, such as those aligned with the Science Based Targets initiative (SBTi) or other climate pledges. This lack of data suggests that Nautilus Biotech S.A. may still be in the early stages of developing its climate strategy or reporting framework. As the industry increasingly prioritises sustainability, it is essential for Nautilus Biotech S.A. to consider implementing measurable climate commitments and reduction initiatives to align with global standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nautilus Biotech S.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
